ArticleAging2013
A healthier approach to clinical trials evaluating resveratrol for primary prevention of age‐related diseases in healthy populations.
Article in Aging, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- The effect of grape products containing polyphenols on oxidative stress: a systematic review and meta-analysis of randomized clinical trials.Nutrition journal · 2021Pooled it
- The Repeated Administration of Resveratrol Has Measurable Effects on Circulating T-Cell Subsets in Humans.Oxidative medicine and cellular longevity · 2017Trial
- Resveratrol for Cancer Radio-Sensitization: Ready for Prime Time or Future Perspective.Food science & nutrition · 2026Review
- Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.Current pharmaceutical design · 2026Review
- Phenolic compounds and epigenetic mechanisms regulating gene expression: effects on human health.Journal of physiology and biochemistry · 2025Review
- Review
- Integrating clinical evidence with natural product therapies for elderly-onset type 2 diabetes.Frontiers in pharmacology · 2025Review
- Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan.Nutrients · 2023Review
- Keeping the beat against time: Mitochondrial fitness in the aging heart.Frontiers in aging · 2022Review
- Immunotoxicity studies of trans-resveratrol in male BJournal of immunotoxicology · 2020Article
- The Interplay Between Antioxidants and the Immune System: A Promising Field, Still Looking for Answers.Nutrients · 2020Article
- Resveratrol and Its Effects on the Vascular System.International journal of molecular sciences · 2019Review
- The Effects of Resveratrol in Patients with Cardiovascular Disease and Heart Failure: A Narrative Review.International journal of molecular sciences · 2019Review
- Article
- Future directions of resveratrol research.Nutrition and healthy aging · 2018Review
- Significance of Resveratrol in Clinical Management of Chronic Diseases.Molecules (Basel, Switzerland) · 2017Review
- Residential proximity to abandoned uranium mines and serum inflammatory potential in chronically exposed Navajo communities.Journal of exposure science & environmental epidemiology · 2017Article
- Serum from obstructive sleep apnea patients induces inflammatory responses in coronary artery endothelial cells.Atherosclerosis · 2016Article
- Challenges in Analyzing the Biological Effects of Resveratrol.Nutrients · 2016Review
- The supplementation effects of peanut sprout on reduction of abdominal fat and health indices in overweight and obese women.Nutrition research and practice · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
In recent years, the wealth of basic science research supporting resveratrol's potential to treat, delay, and even prevent age-related chronic diseases has led to a number of human clinical trials. While such translational research has yielded promising results in clinical populations, recently published conflicting results from studies evaluating resveratrol's potential for primary prevention of chronic disease in healthy / asymptomatic individuals have generated considerable controversy and do not initially appear consistent with findings from animal models. We argue that trials targeting healthy humans are often fundamentally flawed owing to inappropriate use of paradigms only applicable to populations with overt clinical disease and the consequent misleading (typically negative) results can severely retard advancement of drug development. To appropriately perform translational research centered on resveratrol as a primary prevention agent in non-clinical populations, it is critical to utilize study designs which can provide adequate information on clinically relevant outcome measures, avoid paradigms and assumptions from interventions which are specific to clinical populations, and maintain realistic expectations compared to interventions which provide the theoretical maximal response (e.g., caloric restriction and aerobic exercise training).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.